Technology Listings


Respiratory syncytial virus (RSV) Reporter Plasmid for High Throughput Drug Screening

Application

Bioluminescence reporter for high throughput respiratory syncytial virus (RSV) drug discovery.

Key Benefits

Simple luciferase readout marker indicates RSV replication activity.

Market Summary

RSV is a ubiquitous respiratory pathogen worldwide. It is the most common cause of severe lower respiratory tract disease among infants and young children worldwide, with about 160,000 deaths annually. Furthermore, RSV related illness in elderly is also on the rise. Currently there is a dearth of effective drugs against RSV, and there is an urgent need to devise strategies for RSV drug development.

Technical Summary 

Dr. Moore and colleagues at Emory University have generated a reporter plasmid that encodes firefly luciferase under control of RSV transcriptional regulation elements. This bioluminescence reporter indicates for RSV replication activity, and therefore is extremely useful for high throughput screening of potential antiviral compounds. In order to get luciferase activity and identify replication activity, the reporter must be used in conjunction with RSV helper plasmids (see Emory Tech 12104 for description). The simple luciferase readout provides a convenient marker for RSV replication.

Developmental Stage

Plasmid has been engineered and is available for distribution.

View our feature innovation

Patent Information
Tech ID: 12057
Published: 8/22/2012
Category
Research Tools
Drug Discovery
Vaccines

Contact
Cliff Michaels
Assistant Director
Emory University
404-727-3890
ccmicha@emory.edu

Inventor(s)
Martin Moore
Anne Hotard (Lopez-Ona)
Richard Plemper

Keywords
Immunology/Inflammation
Microbiology/Infectious Diseases
Respiratory